Stellate Cells and Mesenchymal Stem Cells in Benign Mammary Stroma Are Associated with Risk Factors for Breast Cancer - an Observational Study

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2018 Mar 1

PMID 29486751

Citations 3

Authors

Bjorn Logi Isfoss

Bo Holmqvist

Elin Sand

Johan Forsell

Helena Jernstrom

Hakan Olsson

Affiliations

Soon will be listed here.

Abstract

Background: It is not known whether stromal cells in benign breast tissue can mediate risk of breast cancer. We recently described aldehyde dehydrogenase 1 A1 (ALDH1) positive (+) cells in morphologically normal breast stroma of premenopausal women, and the data indicated that their distribution is associated with clinical risk factors for breast cancer. The aim of the present study was to define the identities of these cells using histologic and immunohistologic methods, and to investigate associations between those cells and hormonal and genetic risk factors in pre- and postmenopausal women.

Methods: Stroma of morphologically normal tissue was analyzed in samples from 101 well-characterized women whose breasts had been operated. Morphology and immunolabeling were applied to determine cell identities based on the putative stem cell markers ALDH1 and stage-specific embryonic antigen-3 (SSEA3), and immunophenotypes indicating mast cells or stellate cells. The results were compared with the patients' risk factors using regression analysis (two-tailed).

Results: ALDH1+ round/oval cells were associated with low parity in BRCA1/2 carriers (p = 0.022), while in non-BRCA1/2-carriers they were negatively associated with nulliparity (p = 0.057). In premenopausal women ALDH1+ round/oval cells were associated with family history (p = 0.058). SSEA3+ round/oval cells were morphologically and immunohistologically consistent with multilineage stress-enduring (Muse) cells, and these cells were independently associated with the breast cancer risk factors low parity (p = 0.015), family history (p = 0.021), and hormone use after menopause (p = 0.032). ALDH1+ spindle-shaped/polygonal cells were immunohistologically consistent with stellate cells, and were negatively associated with family history of breast cancer (p = 0.001).

Conclusion: This study identified novel stromal cell types in benign breast tissue that have a potential for stratifying women for breast cancer risk.

Citing Articles

Selective estrogen receptor modulators in the prevention of breast cancer in premenopausal women: a review.

Oceguera-Basurto P, Topete A, Oceguera-Villanueva A, Rivas-Carrillo J, Paz-Davalos M, Quintero-Ramos A Transl Cancer Res. 2022; 9(7):4444-4456.

PMID: 35117809 PMC: 8797886. DOI: 10.21037/tcr-19-1956.

Cancer-Associated Fibroblast Subpopulations With Diverse and Dynamic Roles in the Tumor Microenvironment.

Simon T, Salhia B Mol Cancer Res. 2021; 20(2):183-192.

PMID: 34670861 PMC: 9306405. DOI: 10.1158/1541-7786.MCR-21-0282.

Potential protective effect of ALDH-1 stromal expression against early recurrence of operable breast cancers.

Lee J, Kim W Stem Cell Investig. 2019; 5:43.

PMID: 30596083 PMC: 6286887. DOI: 10.21037/sci.2018.11.03.

References

. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1999; 350(9084):1047-59. View

Jernstrom H, Lerman C, Ghadirian P, Lynch H, Weber B, Garber J . Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet. 1999; 354(9193):1846-50. DOI: 10.1016/s0140-6736(99)04336-6. View

Olsson H, Ingvar C, Bladstrom A . Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer. 2003; 97(6):1387-92. DOI: 10.1002/cncr.11205. View

Beral V . Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003; 362(9382):419-27. DOI: 10.1016/s0140-6736(03)14065-2. View

Jernstrom H, Bendahl P, Lidfeldt J, Nerbrand C, Agardh C, Samsioe G . A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: the women's health in the Lund area (WHILA) study (Sweden). Cancer Causes Control. 2003; 14(7):673-80. DOI: 10.1023/a:1025635720208. View

Jernstrom H, Loman N, Johannsson O, Borg A, Olsson H . Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing. Eur J Cancer. 2005; 41(15):2312-20. DOI: 10.1016/j.ejca.2005.03.035. View

Kotsopoulos J, Lubinski J, Lynch H, Klijn J, Ghadirian P, Neuhausen S . Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2007; 105(2):221-8. DOI: 10.1007/s10549-006-9441-3. View

Harvey J, Santen R, Petroni G, Bovbjerg V, Smolkin M, Sheriff F . Histologic changes in the breast with menopausal hormone therapy use: correlation with breast density, estrogen receptor, progesterone receptor, and proliferation indices. Menopause. 2007; 15(1):67-73. PMC: 4567838. DOI: 10.1097/gme.0b013e318054e29a. View

Fackenthal J, Olopade O . Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer. 2007; 7(12):937-48. DOI: 10.1038/nrc2054. View

10.

Friedman S . Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008; 88(1):125-72. PMC: 2888531. DOI: 10.1152/physrev.00013.2007. View

11.

Ginestier C, Hur M, Charafe-Jauffret E, Monville F, Dutcher J, Brown M . ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2008; 1(5):555-67. PMC: 2423808. DOI: 10.1016/j.stem.2007.08.014. View

12.

Marchitti S, Brocker C, Stagos D, Vasiliou V . Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol. 2008; 4(6):697-720. PMC: 2658643. DOI: 10.1517/17425255.4.6.697 . View

13.

Chang W, Lee C, Lee P, Lin J, Hsu C, Hung J . Expression of Globo H and SSEA3 in breast cancer stem cells and the involvement of fucosyl transferases 1 and 2 in Globo H synthesis. Proc Natl Acad Sci U S A. 2008; 105(33):11667-72. PMC: 2575305. DOI: 10.1073/pnas.0804979105. View

14.

Duester G . Retinoic acid synthesis and signaling during early organogenesis. Cell. 2008; 134(6):921-31. PMC: 2632951. DOI: 10.1016/j.cell.2008.09.002. View

15.

Van Rossen E, Vander Borght S, van Grunsven L, Reynaert H, Bruggeman V, Blomhoff R . Vinculin and cellular retinol-binding protein-1 are markers for quiescent and activated hepatic stellate cells in formalin-fixed paraffin embedded human liver. Histochem Cell Biol. 2008; 131(3):313-25. DOI: 10.1007/s00418-008-0544-2. View

16.

Resetkova E, Reis-Filho J, Jain R, Mehta R, Thorat M, Nakshatri H . Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat. 2009; 123(1):97-108. DOI: 10.1007/s10549-009-0619-3. View

17.

Ma H, Henderson K, Sullivan-Halley J, Duan L, Marshall S, Ursin G . Pregnancy-related factors and the risk of breast carcinoma in situ and invasive breast cancer among postmenopausal women in the California Teachers Study cohort. Breast Cancer Res. 2010; 12(3):R35. PMC: 2917030. DOI: 10.1186/bcr2589. View

18.

Wakao S, Kitada M, Kuroda Y, Shigemoto T, Matsuse D, Akashi H . Multilineage-differentiating stress-enduring (Muse) cells are a primary source of induced pluripotent stem cells in human fibroblasts. Proc Natl Acad Sci U S A. 2011; 108(24):9875-80. PMC: 3116385. DOI: 10.1073/pnas.1100816108. View

19.

Isfoss B, Holmqvist B, Alm P, Olsson H . Distribution of aldehyde dehydrogenase 1-positive stem cells in benign mammary tissue from women with and without breast cancer. Histopathology. 2012; 60(4):617-33. DOI: 10.1111/j.1365-2559.2011.04109.x. View

20.

Suzuki Y, Haraguchi N, Takahashi H, Uemura M, Nishimura J, Hata T . SSEA-3 as a novel amplifying cancer cell surface marker in colorectal cancers. Int J Oncol. 2012; 42(1):161-7. DOI: 10.3892/ijo.2012.1713. View